ArticleGut1991
Effects of urogastrone-epidermal growth factor on intestinal brush border enzymes and mitotic activity.
Article in Gut, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Epidermal Growth Factor is Effective in the Treatment of Diabetic Foot Ulcers: Meta-Analysis and Systematic Review.International journal of environmental research and public health · 2019Pooled it
- Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials.Clinical drug investigation · 2019Pooled it
- The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer.Drug design, development and therapy · 2021Review
- Epidermal growth factor attenuates tubular necrosis following mercuric chloride damage by regeneration of indigenous, not bone marrow-derived cells.Journal of cellular and molecular medicine · 2015Article
- The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin.Digestive diseases and sciences · 2010Article
- Epidermal growth factor and bombesin act synergistically to support intestinal adaptation in rats with massive small bowel resection.Pediatric surgery international · 2005Article
- Epidermal growth factor prevents gut atrophy and maintains intestinal integrity in rats with acute pancreatitis.World journal of gastroenterology · 2000Article
- Epithelial stem cell repertoire in the gut: clues to the origin of cell lineages, proliferative units and cancer.International journal of experimental pathology · 2000Article
- Effects of orally administered epidermal growth factor on enteropathogenic Escherichia coli infection in rabbits.Infection and immunity · 1998Article
- Aspects of the biology of regeneration and repair in the human gastrointestinal tract.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 1998Review
- Epidermal growth factor enhances repair of rat intestinal mucosa damaged by oral administration of methotrexate.Journal of gastroenterology · 1995Article
- Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The wet weight of the stomach, small intestine, caecum, and colon were significantly reduced (p less than 0.001) in intravenously fed rats compared with orally fed controls. Human epidermal growth factor (urogastrone) reversed this atrophy. Detailed analysis of the small intestine showed a similar effect on intestinal crypt cell population, mitoses per crypt, and protein content. Brush border gamma glutamyltransferase and alpha glucosidase activities were reduced by up to 50% throughout the small intestine of the animals fed intravenously. The specific activities (mU/mg protein) were unchanged, as a concomitant decrease in the tissue weight and protein content also occurred. Intestinal brush border enzyme activities in the rats treated with urogastrone-epidermal growth factor were restored to those seen in the orally fed rats except for alpha glucosidase activity in the proximal gut. In addition, the specific activity of gamma glutamyltransferase was highly significantly increased (p less than 0.01) in all regions of the small intestine. Thus, although urogastrone administration prevents the decrease in brush border enzyme activity seen after the removal of luminal nutrition, the response seems to differ depending on the intestinal location, with the specific activities of some enzymes being higher than those seen in orally fed rats. Urogastrone-epidermal growth factor can thus significantly increase the functional ability of the intestine in addition to its trophic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.